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Abstract
This study correlated assessment tools for evaluating the severity of skin, nail, and joint symptoms in patients with psoriasis
(Pso) and psoriatic arthritis (PsA). Adults with plaque Pso (with or without PsA) were enrolled from four U.S. institutions.
Patients were evaluated using a novel 10-area Linear Psoriasis Area and Severity Index (XL-PASI), Psoriatic Arthritis
Assessment (PsAA), Psoriatic Arthritis Screening and Evaluation Questionnaire (PASE), Nail Assessment (NA) and Joint
Assessment (JA) tools, Psoriasis Weighted Extent and Severity Index (PWESI), and Lattice Physician Global Assessment (LS-
PGA). Correlations between assessment tools and individual items in the assessment tools were performed. Data from 180
patients (55 with PsA) were analyzed. Highest correlations between tools (r=0.77–0.88) were between the XL-PASI, PWESI
and LS-PGA. Individual items in the XL-PASI correlated with items in the PWESI for extent skin symptoms, but not for all
body areas. Overall, correlations were seen between hands and feet, between face and scalp, and between buttocks, chest,
and back. Only low correlation was seen between items assessing joint symptoms with items assessing skin symptoms.
These data support the notion that the complex phenotype of psoriatic disease requires instruments that assess the severity
of skin, nails, and joints separately.
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Introduction
Psoriasis (Pso) is a chronic, systemic, inflammatory, multigenic
disease, that manifests in the skin and has significant impact on
quality of life [1]. About one quarter of patients with Pso also
develop psoriatic arthritis (PsA) [2]. Nail involvement is common
in patients with Pso and more so with PsA [3]. Recent studies have
suggested that psoriatic skin, joint, and nail manifestations, long
believed to share a common etiology, may be traits of distinct
disease conditions [4–8]. This may explain why the severity and
progression of skin, joint, and nail symptoms are frequently
asynchronous [9], with joint disease in most patients developing up
to 10 years after the initial skin presentation.
Genes within the Major Histocompatibility Complex and genes
encoding cytokines have been linked to Pso and PsA [1,10–14].
Genetic evidence supports the notion that Pso and PsA are two
disease conditions with comorbid association, but might have
distinct genes that drive pathogenesis, progression, and severity
[1,10,15]. Individual alleles for many of these genes and single
nucleotide polymorphisms (SNPs) within these genes appear to be
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20279differentially associated with Pso and PsA. Recently, Nograles
et al. postulated that Pso and PsA involve multiple genes with low
risk effects, only some of which may be shared [16].
Biological evidence also supports a physiological differentiation.
For example, selected key immune mediators of disease in the skin
and joints differ. Pathologic events in the skin are mediated by
autoreactive T cells [1], whereas T cells in the affected synovium
of PsA patients do not exhibit the same type of autoreactivity [17].
Skin and joint symptoms frequently do not respond equally or in
parallel to systemic or biologic therapeutic agents [18].
Hence, there is a need to optimize the diagnosis and recording
of the appearance and progression of Pso and PsA for both clinical
research purposes and clinical practice, thus optimizing treatment
modalities and outcomes. The goal of this paper is to determine
from existing tools the smallest number of independent scoring
dimensions needed to measure the presence and severity of skin,
nail and joint involvement in the broadest psoriatic patient
population. Various assessment tools were then evaluated in a
phase II-type clinical trial.
Methods
Study design
The clinical portion of the study was conducted from November
2007 to August 2008 in four U.S. institutions; Baylor Research
Institute, Dallas; Central Dermatology, St. Louis; University of
Utah, Salt Lake City; and Tufts Medical Center, Boston. The
study protocol and informed consent forms were approved by all
institutional review boards and all patients signed a written
consent form before initiation of study-specific procedures. All
statistical analyses were performed at the Rockefeller University,
Center for Clinical and translational Science, New York.
Patients
Eligible patients were .18 years old and had plaque Pso (with
or without PsA) with $5% and #90% body surface area (BSA)
affected.
Disease assessment tools
As described below, the assessment tools comprised two
categories: those that involved a physician examination and those
submitted to the patient by questionnaire. Some tools were
modified slightly to derive more detailed information and
consequently, these are included as supplemental figures.
Psoriasis Area and Severity Index (PASI). The PASI is the
most commonly used tool to assess disease severity in patients with
Pso in clinical trials [19]. The PASI measures erythema, scaling,
and thickness of lesions and is weighted by the area of
involvement. The PASI scale ranges from 0 to 72, calculated as
the extent of involvement6(score for erythema + score for scaling
+ score for thickness), where the extent of involvement is
categorized as: 0 (0%), 1 (1–9%), 2 (10–29%), 3 (30–49%), 4
(50–69%), 5 (70–89%), or 6 (90–100%), and scores for erythema,
scaling, and thickness are each rated on a scale of 0 to 4. It is
seldom used in clinical practice.
Psoriatic Arthritis Assessment (PsAA). The PsAA (Fig. S1)
is a composite measurement of PsA that includes questions
regarding patient and family history and 6 multipart components
of a physical examination. Psoriatic Arthritis Screening and Evaluation
Questionnaire (PASE). This validated questionnaire (Fig. S2)
comprises seven questions regarding symptoms and eight
questions regarding function that are answered by the patient
[20]. Questions are rated on a scale of 1 (strongly disagree) to 5
(strongly agree).
Nail Assessment (NA) and Joint Assessment (JA). The NA
and JA (Fig. S3) evaluate nail involvement (score 0 for no
involvement and score 1 for involvement by digit) and joint
involvement (0/1 by digit) on the hands. The scoring is based upon
physician assessment. Selected items that evaluate the type of
disease for most involved nail were excluded as several assessors
had included toenails; only fingernail assessments were included in
this analysis.
Psoriasis Weighted Extent and Severity Index (PW-
ESI). This index (Fig. S4) is used to evaluate the extent of skin
disease on a scale of 0 (none) to 4 (extensive) and severity of disease
on a scale of 0 (essentially clear) to (intensely inflamed) (46). Ten
areas are assessed: scalp/hairline, face/neck, arms/axillae, hands/
fingers/fingernails, anterior chest/abdomen, back/shoulders,
genitalia/perineum/natal cleft, buttocks/thighs, knees/lower legs/
ankles, and feet/toes/toenails. The physician assessment delivers a
maximal composite score of 50.
Extended 10-Area Linear Psoriasis Area and Severity
Index (XL-PASI). The XL-PASI (illustrated in Fig. S5) is novel
assessment tool combines the PASI method [19] of scoring severity
separately by erythema, thickness, and scaling with the PWESI
method of dividing the body surface into ten areas. The modified
PASI measure includes assessment of surface area involved, as well
as dimensions for scaling, erythema, thickness and joint
involvement for specific areas of psoriatic involvement. As with
the PASI, severity indicators range from 0 (none) to 4 (extremely
severe). As with the PWESI, body surface area was divided into ten
(‘‘X’’) areas. To increase the granularity of the results, each area
was quantified (‘‘Linearized’’) rather than categorized, i.e., the
proportion of area affected was estimated numerically, rather than
merely broadly categorized as in the PASI. Finally, the PASI was
‘‘eXtended’’ to include severity indicators for arthritis, quality of
life, and sensations (pain/itching), although these additional
measures were not included in this study. The scale of the XL-
PASI ranges from 0 to 148.
Lattice Physician Global Assessment (LS-PGA). The LS-
PGA [21] was included in the analysis of correlations between
assessment tools. The results were deemed not sufficiently detailed
to be included in the itemized analysis.
Data entry
Electronic versions of the instruments were generated using the
Web-based Interactive Study Design, Organization, and Manage-
ment (WISDOM) software, and are available for download at
http://wisdom.rockefeller.edu. The meta data were extracted and
automatically reformatted as screen form definitions for Research
Electronic Data Capturing (REDCap) [22]. Data were entered
twice by different typists and inconsistencies were resolved by an
independent reviewer. One assessor entered the percentage total
body area involvement as the XL-PASI proportion of involved
skin, rather than percentage of body area by region. These data
were analyzed as interval-censored between the highest and lowest
value consistent with the input [23].
Statistical analyses
Statistical analyses were conducted using the mStat server at the
Rockefeller University (http://mustat.rockefeller.edu) for comput-
ing u-scores of the binary, discrete, continuous, and interval-
censored data. JMPH 7.0 software (The SAS Institute, Cary, NC)
was used to generate the heatmap of the scores and Pearson
correlations, equivalent to Spearman rank correlations [24]. R
software (R Foundation, Vienna, Austria; http://cran.r-project.
org) was used to compute odds ratios.
Independent Symptoms in Psoriatic Arthritis
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Patients
Two hundred patients were screened for participation from the
four clinical centers. Data from 180 evaluable patients that met the
screening criteria were included in the analysis (Table 1). Of these,
55 (31%) patients had a diagnosis of PsA (confirmed by a
rheumatologist) at baseline. The majority of patients were
Caucasian (n=154; 86%) and the remaining Asian (n=5; 3%),
Black (n=6; 3%), Hispanic (n=13; 7%), and Native American
(n=2; 1%).
Correlations between assessment tools
Correlations between scoring tools used to assess severity of Pso
and PsA are shown in Figure 1. The highest correlation was seen
between the XL-PASI and the PWESI (r=0.88), which differ in
granularity and relative weight of their components. The LS-PGA
was also reasonably well correlated with the XL-PASI and PWESI
(r=0.79 and 0.77, respectively). The PsAA and the PASE also
demonstrated good correlation (r=0.655), although the self-
assessment tool (PASE) discriminated less between mild and
severe cases. The subsequent detailed analysis showed a surprising
absence of any correlation between these two groups of tools
(PsAA/PASE) and LS-PGA/XL-PASI/PWESI.
Correlations between items in the assessment tools
Correlations between individual items in the scoring tools are
shown in Figure 2. The observations among fingers (or toes) were
highly correlated as indicated for joint involvement (upper left
corner) and nail disease (center). Individual items in the PASI
score and the corresponding PWESI extent score were also highly
correlated, as were the three PASI disease activity scores
(erythema, thickness, and scaling) and the PWESI severity score.
The extent (surface area involved per PASI) and severity (activity
per PASI) of disease were highly correlated for feet, hands,
genitalia/perineum/natal cleft, face, and scalp. In contrast,
severity/activity of arms, knees, buttocks, chest, and back did
not correlate with the extent/involvement across these body areas.
The ‘‘secondary structure’’ of off-diagonal correlations (between
severity/activity and extent/involvement within the same region)
in the lower right corner of Figure 2 indicated that these items
were not independent (see Figure 2 legend for details). Overall,
correlations were seen between hands and feet, face and scalp, and
buttocks, chest, and back.
Little correlation was seen between the PASE, PsAA, and JA
items describing severity of psoriatic arthritis and the PASI,
PWESI, and NA. The only overlap noted among these items was
individual PASE function items and extent and severity of Pso of
the hands and feet. The correlations between hands/feet (XL-
PASI/PWESI) and NA are likely inflated at the expense of the
correlation between hands/feet and Pso of the other body areas
(lower right corner) because of the design and wording of the
questionnaires. Moreover, the NA items were highly correlated
among each other, but had poor correlation with XL-PASI and
PWESI items. Again, hands and feet were an exception, most
notably for the severity by PWESI, which explicitly includes
‘‘fingernails’’ and ‘‘toenails’’ in its ‘‘hands’’ and ‘‘feet’’ categories.
In particular, there were no secondary structures indicating that
the joint and nail symptoms affect the same digits, an observation
in contrast to the commonly believed theory.
Discussion
The results of this study do not support the hypothesis that a
‘‘least common denominator’’ of individual components will
suffice to define the severity of the spectrum of disease along the
axes of both psoriasis and psoriatic arthritis. Thus, at this time, the
need for a single measurement tool that is broadly utilizable with
the ability to measure the presence and severity of all clinical
aspects of psoriasis remains unmet.
Our results provide evidence against an association between the
severity of joint and skin involvement in patients with Pso and PsA,
with the possible exception of hand symptoms. There have been
few studies that have directly addressed the controversial
relationship between the complexities of skin, nail and joint
disease in psoriatic patients. Several small studies have reported no
[25–27] or weak [9] associations between the activity of Pso and
the activity, severity or functional status of the joints. However, a
correlation between skin and joint severity was noted in a small
group of patients who had synchronous onset of PsA and Pso [27].
All of these studies had only small sample sizes and thus low
statistical power. However, in a large phase 4 clinical trial of 1122
patients, Gottlieb et al., found that baseline skin and joint disease
measures were not correlated [28]. While confirming these earlier
findings, the present study is limited in regard to the statistical
power describing the relationship of specific psoriatic arthritis
subtypes or extent of psoriatic disease. Therefore, based upon
these initial unexpected observations, a more robust analysis would
be necessary to better investigate the skin-joint relationship.
However, in support of previous observations regarding a
qualitative association between skin and joint disease [2], and
consistent with both disease conditions sharing at least some
genetic risk factors, we did find a high odds ratio (19.9; P,0.001)
for skin involvement and ‘‘any joints involved’’ and ‘‘any nail
involved’’ among toes and a moderate odds ratios (2.0; P=0.079)
for fingers. The lack of a quantitative association requires further
investigation but might involve additional genetic risk factors.
Several inconsistencies in the design of individual instruments
may have affected our results. The PWESI explicitly includes nails
with hands and feet, but the guidelines provided on the form do
not allow even the most severe nail disease to be marked more
than ‘‘noticeable’’ in terms of extent. The XL-PASI (like the
PASI), in contrast, does not mention nails at all. The diversity of
Pso manifestations on the hands and feet (palmarplantar disease)
for example hyperkeratosis vs pustular or combinations thereof,
further complicates the issue (Farley et al., 2009). The relatively
Table 1. Patient demographics at baseline.
Psoriasis
1
n=182
PsA
1
n=68
Nail
Disease
1
n=112
Sex (Female/Male) 84/98 32/36 43/69
Mean age - years (SD)
Minimum, maximum
45.3 (15.0)
18, 84
47.8 (13.6)
20, 72
47.8 (13.8)
20, 84
Mean weight - kg (SD)
Minimum, maximum
204.9 (52.3)
97, 377
207.5 (52.7)
97, 350
209.1 (51.2)
97, 377
Mean height - in (SD)
Minimum, maximum
67.4 (4.3)
50, 78
67.5 (3.8)
59, 76
67.6 (4.2)
50, 76
Patients with PsA
diagnosis by a
rheumatologist – n (%)
55 (30%) 53 (78%) 40 (36%)
1Self-reported.
Abbreviations: PsA, Psoriatic arthritis; SD, Standard deviation.
doi:10.1371/journal.pone.0020279.t001
Independent Symptoms in Psoriatic Arthritis
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in nails and hands/feet and the extremely low correlation between
extent of disease in hands/feet and extent of disease in all other
body areas may suggest that the examiners attempted to reflect
severe nail disease by inflating extent and severity of skin disease of
hands and feet. The XL-PASI includes a column for severity of
arthritis, so that physicians were less likely to reflect joint problems
by increasing the severity indicators meant to reflect skin
conditions. The PWESI, by contrast, has no separate category
for arthritis and, in support of this argument, had a higher
correlation with severity of arthritis than the PASI.
Analysis of data to evaluate nail disease was complicated by
wording of the assessment tools. The NA includes a request for a
list of all involved digits (fingers and toes), but then continues with
‘‘Select the most involved fingernail and evaluate.’’ Several
completed questionnaires indicated that the examiner had
included toenails in the assessment, but others may have followed
the instructions literally so that the assessment could be biased to
disease forms more frequently seen with hands, such as pitting.
This issue highlights the importance of validating assessment tools
in the appropriate clinical setting. These observations suggest that
Pso of the nails might be more clearly separated from Pso of the
skin if examiners were allowed to distinguish explicitly between
involvement of nails and skin on both hands and feet.
The pathophysiology of nail dystrophy has been postulated to
be more closely associated with joint symptoms than with skin
symptoms [4]. As with the hands and feet, there is a great diversity
in the clinical manifestations of nail disease, with the added
problem of secondary infections (bacterial, fungal) aggravating or
masking the manifestations, particularly in psoriatic toenails. PsA
has been more strongly associated with nail disease than Pso alone
[29]. Imaging studies have shown that the nail and the enthesis
(the point at which tendons attach to bones) are linked via the
distal interphalangeal joint extensor tendon [30,31]. This close
Figure 1. Correlations between tools scoring the severity of psoriasis and psoriatic arthritis and distribution of scores. x-axis and y-
axis values represent the respective scores of the tools. For comparison with traditional PASI scores, the XL-PASI scores are translated into estimated
PASI scores. The dotted line with an estimated PASI score of 12 separates the patients with moderate and severe disease. r: Spearman correlation.
doi:10.1371/journal.pone.0020279.g001
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the association between these symptoms, particularly relating to
distal interphalangeal joint involvement and nail disease.
GWAS and family-based association tests for Pso as a whole
have had only limited success in defining causative alleles. The
results presented here, however, offer a strategy for future genetic
studies with a high potential for success in elucidating genetic risk
factors for Pso. More specific and statistically validated assessment
instruments will allow for the clinical classification of Pso patients
into specific categories based on skin, joint, and nail involvement.
In addition, the identification of genetic discriminators between
these categories, using novel multivariate [23], multi-locus [32],
and multi-allelic [33] nonparametric methods in a well-defined
subpopulation of patients with the same underlying condition,
would be more accurate than studies using traditional methods for
univariate, single-locus, or binary data in the more diverse
population as a whole.
The clinical evidence presented herein likely signifies the
existence of different psoriatic disease phenotypes, thus supporting
the hypothesis that different genetic risk factors are involved in the
Figure 2. Correlations between individual items of psoriasis and psoriatic arthritis severity. Each cell indicates the Spearman correlation
between 2 of the 52 items. Cells with dark red indicates strong positive correlation, light red indicates weak positive correlation, dark green indicates
strong negative correlation, and light green indicates weak negative correlation. Boxes in the upper left portion indicate correlations between
affected nails and joints on hands and feet. Boxes in the lower right corner indicate ‘‘secondary structure’’ (within-box diagonal) between extent/
involvement and severity/activity within regions. JA: Joint Assessment; NA: Nail Assessment; PASE: Psoriatic Arthritis Screening and Evaluation
Questionnaire; PsAA: Psoriatic Arthritis Assessment; XL-PASI: Extended 10-area Linear Psoriasis Area and Severity Index; PWESI: Psoriasis Weighted
Extent and Severity Index.
doi:10.1371/journal.pone.0020279.g002
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Our results suggest that the complex phenotype of psoriatic disease
can only be assessed with instruments that allow the examiner to
judge severity of skin, nails, and joints separately (in addition to
extent of skin involvement). Moreover, the data analysis suggests
that a minimum of two summary scores (one for skin and one for
joints), and potentially a third for nails, are required to accurately
assess severity across the full spectrum of psoriatic disease. The
optimal design of such assessment tools remains the objective of
this research project, with efforts continuing to identify the most
meaningful contributing elements that define the full spectrum of
the psoriatic disease state. Accordingly, this information is likely to
be of significant benefit clinical practice as well as in the future
design of clinical trials investigating developmental therapies for
Pso and PsA.
Supporting Information
Figure S1 Psoriatic Arthritis Assessment (PsAA) is a
composite measurement of PsA that includes questions
regarding patient and family history and 6 multipart
components of a physical examination.
(TIF)
Figure S2 Psoriatic Arthritis Screening and Evaluation
(PASE) is a validated patient questionnaire that com-
prises questions on symptoms and functions.
(TIF)
Figure S3 Nail Assessment (NA) and Joint Assessment
(JA) evaluates nail involvement (score 0 for no involve-
ment and score 1 for involvement by digit) and joint
involvement (0/1 by digit) on the hands, as determined
by physician assessment.
(TIF)
Figure S4 Psoriasis Weighted Extent and Severity Index
(PWESI) is used to evaluate the extent and severity of
skin disease across multiple areas of the body. The extent
of skin disease is measured on a scale of 0 (none) to 4 (extensive)
and severity of disease on a scale of 0 (essentially clear) to (intensely
inflamed). Ten areas are assessed: scalp/hairline, face/neck, arms/
axillae, hands/fingers/fingernails, anterior chest/abdomen, back/
shoulders, genitalia/perineum/natal cleft, buttocks/thighs, knees/
lower legs/ankles, and feet/toes/toenails. This physician assess-
ment delivers a maximal composite score of 50.
(TIF)
Figure S5 Extended 10-area Linear Psoriasis Area and
Severity Index (XL-PASI) combines the PASI and PWESI
scoring methods. This measure includes assessment of surface
area involved, as well as dimensions for scaling, erythema,
thickness and joint involvement for specific areas of psoriatic
involvement. As with the PASI, severity indicators range from 0
(none) to 4 (extremely severe). As with the PWESI, body surface
area is divided into ten (‘‘X’’) areas and each area is quantified.
The scale of the XL-PASI ranges from 0 to 148.
(TIF)
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